STAT Plus: Sarepta sells international rights to Duchenne gene therapy to Roche

From BioPortfolio: Sarepta will receive $1.15 billion in cash and an equity investment from Roche in exchange for international rights to its experimental gene therapy for Duchenn…

Read the full article here

Related Articles